{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Necrotising colitis', 'Neutropenic colitis', 'Acute hepatic failure', 'Autoimmune cholangitis', 'Autoimmune hepatitis', 'Hepatic failure', 'Hepatic function abnormal', 'Hepatitis', 'Hepatitis acute', 'Hepatotoxicity', 'Hyperbilirubinaemia', 'Immune-mediated cholangitis', 'Immune-mediated hepatic disorder', 'Immune-mediated hepatitis', 'Jaundice', 'Liver injury', 'Alanine aminotransferase increased', 'Aspartate aminotransferase increased', 'Blood bilirubin increased', 'Gamma-glutamyltransferase increased', 'Hepatic enzyme increased', 'Liver function test abnormal', 'Transaminases increased', 'Autoimmune hyperlipidaemia', 'Regeneron Pharmaceuticals, Inc.', 'Page 136 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Autoimmune inner ear disease', 'Blood creatinine increased', 'Glomerular filtration rate decreased', 'Acute kidney injury', 'Autoimmune nephritis', 'Chronic autoimmune glomerulonephritis', 'Immune-mediated nephritis', 'Immune-mediated renal disorder', 'Lupus nephritis', 'Nephritis', 'Nephritis haemorrhagic', 'Perinephritis', 'Renal failure', 'Renal impairment', 'Tubulointerstitial nephritis', 'Tubulointerstitial nephritis and uveitis syndrome', 'Autoimmune neutropenia', 'Autoimmune pancytopenia', 'Immune-mediated pancytopenia', 'Acute interstitial pneumonitis', 'Autoimmune lung disease', 'Immune-mediated pneumonitis', 'Interstitial lung disease', 'Pneumonitis', 'Regeneron Pharmaceuticals, Inc.', 'Page 137 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Autoimmune retinopathy', 'Rash pustular', 'Perineal rash', 'Acute generalised exanthematous pustulosis', 'Autoimmune blistering disease', 'Autoimmune dermatitis', 'Dermatitis', 'Dermatitis acneiform', 'Dermatitis bullous', 'Dermatitis exfoliative', 'Dermatitis exfoliative generalised', 'Dermatitis herpetiformis', 'Drug eruption', 'Drug reaction with eosinophilia and systemic symptoms', 'Dyshidrotic eczema', 'Erythema', 'Erythema multiforme', 'Erythema nodosum', 'Exfoliative rash', 'Immune-mediated dermatitis', 'Lichen planus', 'Oculomucocutaneous syndrome', 'Palmoplantar keratoderma', 'Parapsoriasis', 'Regeneron Pharmaceuticals, Inc.', 'Page 138 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}